肿瘤患者血清线粒体肌酸激酶水平变化及其诊断意义研究进展*

doi:10.3969/j.issn.1672-5069.2015.02.033

摘要/Abstract

摘要： 线粒体肌酸激酶（MtCK）存在于细胞内线粒体内膜和外膜间隙，属肌酸激酶同工酶系列，其主要生理作用是在有氧情况下通过磷酸肌酸穿梭机制提供肌肉收缩所需能量。近年来，很多研究发现 MtCK 在肿瘤患者血清中高表达，且大多数是患有恶性肿瘤患者的血清中 MtCK 呈高表达，在预后不好的病人中过表达尤其明显，推测其对恶性肿瘤的临床诊断及预后判断具有重要意义。同时，分子生物学研究认为MtCK 过表达可以使细胞在某种程度上获得一定的生长优势以抵抗调亡。

关键词: 肿瘤, 线粒体肌酸激酶, 临床诊断

Abstract: Mitochondrial creatine kinase（MtCK） located in the space between inner membrance and outer membrance of intracellular mitochondria. Creatine kinase is a member of the creatine kinase isozyme. The mainly physiological function of MtCK is to provide the energy for muscle contraction through the creatine phosphate shuttle mechanism under aerobic condition， which plays an important role in mitochondrial respiratory control. Recently，over expression of ubiquitous MtCK（uMtCK） is found in malignant tumors with especially poor prognosis. The molecular biology mechanism of the over expression in malignant tumors is well studied and the scholars find that uMtCK might be useful in the diagnosis of malignant tumors. Meanwhile，molecular biology studies shows that over expression of uMtCK promotes malignant tumors growth though resisting apoptosis. We reviewed the role and molecular biologic mechanism of mitochondrial creatine kinase in the diagnosis of malignant tumor.

Key words: Neoplasma, Mitochondrial creatine kinase, Clinical diagnosis

张宁宁，陆伟. 肿瘤患者血清线粒体肌酸激酶水平变化及其诊断意义研究进展^*[J]. 实用肝脏病杂志, 2015, 18(4): 445-448.

Zhang Ningning，Lu Wei. Serum mitochondrial creatine kinase levels in the diagnosis of patients with malignant tumor[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 445-448.

参考文献

[1] Brdiczka D，Beutner G，Ruck A，et al. The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition. Biofactors，1998，8（3）：235-242.
[2] Speer O，Back N，Buerklen T，et al. Octameric mitochondrial creatine kinase induces and stabilizes contact sites between the inner and outer membrane. Biochem J，2005，385（2）： 445-450.
[3] Vernoux N，Granjon T，Marcillat O，et al. Interfacial behavior of cytoplasmic and mitochondrial creatine kinase oligomeric states. Biopolymers，2006，81（4）：270-281.
[4] Schiemann S，Schwirzke M. Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer. Clin Exp Metastasis， 1998，16（2）：129-139.
[5] Schlattner U，Tokarska-Schlattner M，Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta，2006，1762（2）：164-180.
[6] Pratt R，Vallis LM，Lira CW，et a1. Mitoehondrial creatine kinase in cancer patients. Pathology，1987，19（2）：162-165.
[7] Meffert G，Gellerich FN，Margreiter R，et al. Elevated creatine kinase activity in primary hepatocellular carcinoma. BMC Gastroenterol，2005，5：9.
[8] Ruiz Gines MA，Calafell Mas MF，Ruiz Gines JA，et al. Macro creatine kinase：illness marker，practical guide for the management. An Med Interna，2006，23（6）：272-275.
[9] Lee YC，Chamg KJ，Lu FJ，et al. Serum macrocreatine kinase type 2 as a tumor in lung cancer：comparison with carcino embryonic antigen. Formos Med Assoc，1990，89（2）：104-109.
[10] 成继民，陈兴，张哲. 线粒体肌酸激酶在肺癌组织中的表达. 中国肿瘤临床，2000，27（1）：12-13.
[11] 张淇哲，王晓玲，张敬一，等. 106例肺癌组织中线粒体肌酸激酶免疫组化的研究. 中国肿瘤临床与康复，1997，4（3）：4.
[12] Qian XL，Li YQ，Gu F，et al. Overexpression of ubiquitous mitochondrial creatine kinase（uMtCK） accelerates tumor growth by inhibiting apoptosis of breast cancer cells and is associated with a poor prognosis in breast cancer patients. Biochem Biophy Res Commun，2012，427：60-66.
[13] 成继民，陈兴，张乃哲. 线粒体肌酸激酶在乳腺肿瘤的表达及意义. 现代诊断与治疗，1997，8 （1）：10-11.
[14] Cimino L，Fuso C，Sfiligoi N，et al. Identification of new genes associated with BC progression by gene expression analysis of predefined sets of neoplastic tissues. Int J Cancer，2008，123：1327-1338.
[15] Meffert G，Gellerich FN，Margreiter R，et al. Elevated creatine kinase activity in primary hepatocellular carcinoma. BMC Gastroenterol，2005，5：9.
[16] Fadhil J，Toma A，Munaf S. Behavior of creatine kinase isoenzymes in hepatic diseases. Kufa Med J，2008，11（1）：501-507.
[17] Soroida Y，Ohkawa R，Nakagawa H，et al. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol，2012，57：330-336.
[18] 钱琤，于嘉屏，王爱华，等.实时荧光定量 PCR 检测结直肠腺癌患者组织中广泛型线粒体肌酸激酶基因的表达.现代诊断与治疗，2008，23（2）：6-8.
[19] Koven IH，Freedman M，Miler D，et a1. Macrocreatine kinase 2：a possible marker of gastrointestinal cancer Surgery，1983，94（4）：631-635.
[20] Mercer DW，Talamo TS. Multiple markers of malignancy in sera of patients with colorectal carcinoma：preliminary clinical studies. Clin Chem，1985，31（11）：1824-1828.
[21] 顾鹏飞，张建，仲人前，等. 结直肠腺癌患者血清线粒体肌酸激酶检测的意义. 检验医学，2006，21（2）：129-130.
[22] Dang C.V，Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem Sci，1999，25（24）68-72.
[23] Schlattner U，Tokarska M，Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim biophys Acta，2006，1762（2）：164-180.
[24] Miller J， Halow P，Koretsky. Phosphocreatine protects transgenic mouse liver expressing creatine kinase from hypoxia and ischemia. Am. J Physiol，1993，265：1544-1551.
[25] Hatano A，Tanaka S，Iwata S，et al. Induction of endotoxin to lerance in transgenic mouse liver expressing creatine kinase. Hepatology，1996，24：663-666.
[26] Hatano E，Tanaka A，Kanazawa A，et al. Inhibition of tumor necrosis factor-induced apoptosis in transgenic mouse liver expressing creatine kinase. Liver Int，2004，32（24），384-393.
[27] Holtzman A，Togliatti I，Khait F，et al. Creatine increases survival and suppresses seizures in the hypoxic immature rat. Pediatr Res，1998，44：410-414.
[28] Carter AJ，Muller RE，Pschorn U，et al. Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. Neurochem，1995，64：2691-2699.
[29] 周建华，丛国正，高闪电，等.细胞凋亡的研究进展.生物技术通讯，2008，19，2：274-276.
[30] 汪建初. 凋亡抑制蛋白IAPs与恶性肿瘤.右江民族医学院学报，2002，24，6：890-891.
[31] Stewart JH， Nguyen D，Cheng A，et a1. Induction of apoptosis in malignant pleural mesothelioma cells by activation of the fas（Apo-1/CD95） death signal path way. Thorac Cardiovasc Surg，2002，123（2）：295-302.
[32] Ldegerwood C，Pober G，Bradley R，et a1. Recent advances in the molecular basis of TNF signal transduction. Lab Invest，1999，79（13）：1041-1050.
[33] Zamzami N，Kroemer G. The mitochondrion in apoptosis： how pandora’s box opens. Nat Rev Mol Cell Biol，2001，2（1）：67-67.
[34] Kornacker U，Schlattner T，Wallimann R，et al. Hodgkin diseased arived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. Int J Cancer，2001，94：513-519.
[35] Ferrington A，Tran N，Kathleen L. Different death stimuli evoke apoptosis via multiple pathways in retinal pigment epithelial cell. Exp Eye Res，2006，83：638-650.
[36] Eskes R，Ddsagher S，Antonsson B，et a1. Bid induces the oligo merlzation and insertion of Bax into the outermitee hondrial embrane. Mol Cell Bid，2000，20（3）：929-935.
[37] Waterhouse J，Riccl E，Green R. And all of a sudden it' s over mitochondrial outer membrane permeabilization in apoptosis. Biochime，2002，84：113-121.
[38] Ly D，Grubb R，Lawen A. The mitochondrial membrane potential in apoptosis：an update. Apoptosis，2003，28：115-128.
[39] Kwon S，Kim D，Rhee JW，et al. ASB9 interacts with ubiquitous mitochondrial creatine kinase and inhibits mitochondrial function. BMC Biol，2010;8：23.
[40] Bergnes G，Yuan W，Khandekar VS，et al. Creatine and phosphocteatine analogs：anticancer activity and enzymatic analysis. Oncol Res，1996，8（3）：121-130.
[41] Qin W，Khuchua Z，Klein C，et a1. Elements regulating cardiomyocyte expression of the human sarcomeric mitochondrial creatine kinase gene in transgenic mice. J Biol Chem，1997，272（40）：25210-25216.
[42] Payne RM，Straus AW. Developmental expression of sarcomeric ubiquitous mitochondrial creatine kinase is tissue specific. Biochem Biothys Acta，1994，1219（1）：33-38.

肿瘤患者血清线粒体肌酸激酶水平变化及其诊断意义研究进展^*

Serum mitochondrial creatine kinase levels in the diagnosis of patients with malignant tumor

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	叶显俊, 何年安, 隋秀芳, 刘力. 二维超声和超声造影检查肝脏上皮样血管内皮瘤表现特征分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 904-907.
[2]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[3]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[4]	代晓楠, 吕金燕, 翁文采, 郑丽丽. 肝癌组织IFITM3蛋白表达水平及其与肝细胞癌患者手术切除术后肝内肿瘤复发的相关性分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 117-120.
[5]	杨小勇, 李文美, 宋庆伟, 葛颂, 李向农. 功能保留性胰腺手术治疗胰腺神经内分泌肿瘤患者疗效和预后研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 971-974.
[6]	王小华, 王伟, 张妮, 相祎. 血清NGAL联合肌酐早期判断乙型肝炎肝硬化患者并发肝肾综合征的临床价值分析[J]. 实用肝脏病杂志, 2018, 21(5): 685-688.
[7]	伍家彬, 谢晓海. 丙泊酚对肝部分切除术治疗的原发性肝癌患者外周血淋巴细胞亚群和血清肿瘤相关标志物水平的影响[J]. 实用肝脏病杂志, 2018, 21(5): 745-748.
[8]	宋绍团. 椎旁阻滞对肝癌切除患者外周血循环肿瘤细胞和T淋巴细胞亚群的影响[J]. 实用肝脏病杂志, 2018, 21(4): 517-520.
[9]	黄建文, 杨友超, 徐长青, 文天夫. 根治性切除治疗原发性肝癌患者预后分析^*[J]. 实用肝脏病杂志, 2018, 21(4): 521-524.
[10]	秦维, 陈宇萍, 杨昭, 祝素平, 霍玉玲, 李木松. 原发性胆汁性肝硬化患者肝组织转化生长因子β-1表达水平变化[J]. 实用肝脏病杂志, 2018, 21(2): 237-240.
[11]	李国涛, 臧珂, 殷荣坤. CIK细胞在原发性肝癌三维适形放疗联合TACE治疗中的应用研究[J]. 实用肝脏病杂志, 2018, 21(2): 265-268.
[12]	梁长华, 毛华杰, 岳军艳, 张会杰, 王东东, 户彦龙, 窦文广, 高剑波. 320排容积CT全肿瘤灌注测量与常规轴位最大层面测量对肝细胞癌诊断价值的对比分析^*[J]. 实用肝脏病杂志, 2018, 21(1): 88-91.
[13]	孙启峰, 赵志强, 周童, 张启文. 腹腔镜肝部分切除术治疗肝癌患者血清肿瘤标志物的变化[J]. 实用肝脏病杂志, 2018, 21(1): 121-122.
[14]	梁亮,张寅斌，昝瑛，张扬，张淑群. 肝细胞癌组织miR-139水平及其靶基因功能的生物信息学分析[J]. 实用肝脏病杂志, 2017, 20(5): 554-558.
[15]	李宗超，刘乙锦，陈玉辉，魏武. 椎旁阻滞术对肝胆手术患者术后疼痛评分和血清细胞因子水平的影响[J]. 实用肝脏病杂志, 2017, 20(5): 584-587.